CeNeRx, expecting trial results and drug partner in 2012, raises $4.8M
December 9, 2011
Central nervous system drug development company CeNeRx BioPharma is developing an antidepressant whose novel mechanism causes fewer side effects, and the company is now in active talks with large pharmaceutical companies who could take the candidate, called TriRima, into phase 3 studies.
© 2021 Pappas Capital, LLC. ALL RIGHTS RESERVED.